Peroxiredoxin proteins protect MCF-7 breast cancer cells from doxorubicin-induced toxicity

We show that these cells have both higher resistance to doxorubicin‐induced toxicity and significantly elevated Prdx levels, compared to the non‐cancer MCF-10A cells



Scholarcy highlights

  • The peroxiredoxins are a ubiquitous family of evolutionarily conserved antioxidant proteins that reduce aqueous and lipid peroxides associated with normalKey words: peroxiredoxins, antioxidants, MCF-7, breast cancer, cell death, doxorubicin metabolism
  • Analysis of peroxiredoxin protein expression in these two lines revealed that expression of five of the six Prdx proteins are markedly elevated in MCF-7 cells, as compared to MCF-10A cells. These data show a correlation between doxorubicin resistance and peroxiredoxin expression in MCF-7 cells
  • Since our data suggested a role for Prdxs in doxorubicin resistance in MCF-7 cells, we asked whether long-term treatment of these cells and selection of a highly resistant subline would lead to a concomitant change in Prdx levels
  • We showed a correlation between doxorubicin-resistance and peroxiredoxin levels between MCF-7 and MCF-10A cells, demonstrating significantly higher resistance and Prdx expression in the cancer line
  • We demonstrated that 2-week treatment of MCF-7 cells with doxorubicin leads to a marked induction of several Prdx proteins
  • Cells were assayed for MTT at a confluency less than 80%
  • These data support our hypothesis that Prdxs play a protective role in MCF-7 cells and that doxorubicin-treatment leads to selection of drug-resistant cells that possess elevated Prdx levels
  • Our data are the first to report an effect of doxorubicin treatment on Prdx expression in breast cancer cells, as well as a protective role for the peroxiredoxin protein family in breast cancer cell resistance to doxorubicin

Need more features? Save interactive summary cards to your Scholarcy Library.